Possibility as an anti-cancer drug of astemizole: Evaluation of arrhythmogenicity by the chronic atrioventricular block canine model
Since astemizole in an oral dose of 50 mg/kg/day was recently reported to exert anti-cancer effect in mice, we evaluated its proarrhythmic potential using the atrioventricular block dogs in order to clarify its cardiac safety profile. An oral dose of 3 mg/kg prolonged the QT interval without affecti...
Main Authors: | Hiroko Izumi-Nakaseko, Yuji Nakamura, Xin Cao, Takeshi Wada, Kentaro Ando, Atsushi Sugiyama |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2016-06-01
|
Series: | Journal of Pharmacological Sciences |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1347861316300524 |
Similar Items
-
The combination astemizole–gefitinib as a potential therapy for human lung cancer
by: Chávez-López MDG, et al.
Published: (2017-12-01) -
Risperidone alone did not induce torsade de pointes: Experimental evidence from the chronic atrioventricular block model dogs
by: Yoshio Nunoi, et al.
Published: (2020-08-01) -
Intravenous anti-influenza drug oseltamivir will not induce torsade de pointes: Evidences from proarrhythmia model and action-potential assay
by: Yuji Nakamura, et al.
Published: (2016-05-01) -
In vivo analysis of the effects of intravenously as well as orally administered moxifloxacin on the pharmacokinetic and electrocardiographic variables along with its torsadogenic action in the chronic atrioventricular block cynomolgus monkeys
by: Ai Goto, et al.
Published: (2020-08-01) -
Eag1 channels as potential early-stage biomarkers of hepatocellular carcinoma
by: Chávez-López MG, et al.
Published: (2016-09-01)